BioNexus Gene Lab Corp. (BGLC)
- Previous Close
0.3000 - Open
0.3000 - Bid 0.2030 x 200
- Ask 0.3900 x 200
- Day's Range
0.3000 - 0.3000 - 52 Week Range
0.2810 - 3.3900 - Volume
12,952 - Avg. Volume
386,057 - Market Cap (intraday)
5.39M - Beta (5Y Monthly) 1.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioNexus Gene Lab Corp., through its subsidiary, sells chemical raw material products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company offers chemical raw material products, which include Polyester Resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; Polyester Resin 9509, a general-purpose material used in production of marine boats and water slides; and Polyester Resin 2802 used as a component in the pultrusion process by certain manufacturers. Its products are used to produce handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms, and covers for various instruments used in manufacturing. The company also involves in developing and providing non-invasive liquid biopsy tests for the early detection of biomarkers to detect potential risk of diseases. It markets its products through its website, warehouse, marketing personnel, and suppliers. The company was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
www.bionexusgenelab.com30
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BGLC
View MorePerformance Overview: BGLC
Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BGLC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BGLC
View MoreValuation Measures
Market Cap
5.39M
Enterprise Value
1.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.58
Price/Book (mrq)
0.57
Enterprise Value/Revenue
0.16
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-24.01%
Return on Assets (ttm)
-10.11%
Return on Equity (ttm)
-28.44%
Revenue (ttm)
9.18M
Net Income Avi to Common (ttm)
-2.21M
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
5.41M
Total Debt/Equity (mrq)
4.73%
Levered Free Cash Flow (ttm)
-190.55k